TY - JOUR
T1 - Abcb11 deficiency induces cholestasis coupled to impaired β-fatty acid oxidation in mice
AU - Zhang, Yuanyuan
AU - Li, Fei
AU - Patterson, Andrew D.
AU - Wang, Yao
AU - Krausz, Kristopher W.
AU - Neale, Geoffrey
AU - Thomas, Sarah
AU - Nachagari, Deepa
AU - Vogel, Peter
AU - Vore, Mary
AU - Gonzalez, Frank J.
AU - Schuetz, John D.
PY - 2012/7/13
Y1 - 2012/7/13
N2 - The bile salt export pump (BSEP) is an ATP-binding cassette transporter that serves as the primary system for removing bile salts from the liver. In humans, deficiency of BSEP, which is encoded by the ABCB11 gene, causes severe progressive cholestatic liver disease from early infancy. In previous studies of Abcb11 deficiency in mice generated on a mixed genetic background, the animals did not recapitulate the human disease. We reasoned that ABCB11 deficiency may cause unique changes in hepatic metabolism that are predictive of liver injury. To test this possibility, we first determined that Abcb11 knock-out (KO) C57BL/6J mice recapitulate human deficiency. Before the onset of cholestasis, Abcb11 KO mice have altered hepatic lipid metabolism coupled with reduced expression of genes important in mitochondrial fatty acid oxidation. This was associated with increased serum free-fatty acids, reduced total white adipose, and marked impairment of long-chain fatty acid β-oxidation. Importantly, metabolomic analysis confirmed that Abcb11 KO mice have impaired mitochondrial fatty acid β-oxidation with the elevated fatty acid metabolites phenylpropionylglycine and phenylacetylglycine. These metabolic changes precede cholestasis but may be of relevance to cholestatic disease progression because altered fatty acid metabolism can enhance reactive oxygen species that might exacerbate cholestatic liver damage.
AB - The bile salt export pump (BSEP) is an ATP-binding cassette transporter that serves as the primary system for removing bile salts from the liver. In humans, deficiency of BSEP, which is encoded by the ABCB11 gene, causes severe progressive cholestatic liver disease from early infancy. In previous studies of Abcb11 deficiency in mice generated on a mixed genetic background, the animals did not recapitulate the human disease. We reasoned that ABCB11 deficiency may cause unique changes in hepatic metabolism that are predictive of liver injury. To test this possibility, we first determined that Abcb11 knock-out (KO) C57BL/6J mice recapitulate human deficiency. Before the onset of cholestasis, Abcb11 KO mice have altered hepatic lipid metabolism coupled with reduced expression of genes important in mitochondrial fatty acid oxidation. This was associated with increased serum free-fatty acids, reduced total white adipose, and marked impairment of long-chain fatty acid β-oxidation. Importantly, metabolomic analysis confirmed that Abcb11 KO mice have impaired mitochondrial fatty acid β-oxidation with the elevated fatty acid metabolites phenylpropionylglycine and phenylacetylglycine. These metabolic changes precede cholestasis but may be of relevance to cholestatic disease progression because altered fatty acid metabolism can enhance reactive oxygen species that might exacerbate cholestatic liver damage.
UR - http://www.scopus.com/inward/record.url?scp=84863788678&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863788678&partnerID=8YFLogxK
U2 - 10.1074/jbc.M111.329318
DO - 10.1074/jbc.M111.329318
M3 - Article
C2 - 22619174
AN - SCOPUS:84863788678
SN - 0021-9258
VL - 287
SP - 24784
EP - 24794
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 29
ER -